Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
About this item
Full title
Author / Creator
Publisher
Waltham, MA: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Waltham, MA: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Many melanomas contain an activating mutation in BRAF: a substitution of glutamic acid for valine at amino acid 600 (the V600E mutation). The authors conducted a two-phase study to describe the activity of a new agent, PLX4032, that inhibits mutated BRAF. A total of 26 of 32 patients (81%) who received 960 mg of PLX4032 orally, twice daily, had a p...
Alternative Titles
Full title
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3724529
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3724529
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1002011
